The visual inspection of a suspicious skin lesion using the naked eye alone is not enough to ensure the accurate diagnosis of skin cancer, a group of experts have concluded following a largescale systematic review of research.

Published today in The Cochrane Library, the Special Collection of Cochrane Systematic Reviews brings together a review of a large body of research on the accuracy of tests used to diagnose skin cancer. The suite of eleven reviews was led by Dr Jac Dinnes at the University of Birmingham and supported by the Cochrane Skin Group and a team of over 30 researchers and expert advisors. The work was funded by the National Institute for Health Research (NIHR).

The reviews summarise research evidence assessing the accuracy of different diagnostic tests to support clinical and policy related decision making in the diagnosis of all types of skin cancer.

Dr Jac Dinnes, of the University of Birmingham’s Institute of Applied Health Research, said: “Early and accurate detection of all skin cancer types is essential to manage the disease and to improve survival rates in melanoma, especially given the rate of skin cancer world-wide is rising.

“The visual nature of skin cancer means that it can be detected and treated in many different ways and by a number of different types of specialists, therefore the aim of these reviews is to provide the world’s best evidence for how this endemic type of cancer should be identified and treated.

“We have found that careful consideration should be given of the technologies that could be used to make sure that skin cancers are not missed, at the same time ensuring that inappropriate referrals for specialist assessment and inappropriate excision of benign skin lesions are kept to a minimum.”

There are three main forms of skin cancer. Melanoma and cutaneous squamous cell carcinoma (cSCC), are high-risk skin cancers with the potential to spread and cause death. A basal cell carcinoma (BCC) rarely spreads, usually remaining localised with potential to infiltrate and damage surrounding tissue.

Key findings of the Special Collection were:

• Visual inspection using the naked eye alone is not good enough and melanomas may be missed.
• Smartphone applications used by people with concerns about new or changing moles or other skin lesions have a high chance of missing melanomas.
• When used by specialists, dermoscopy - a technique using a handheld device to zoom in on a mole and the underlying skin - is better at diagnosing melanoma than visual inspection alone, and may also help in the diagnosis of BCCs.
• Dermoscopy might also help GPs to correctly identify people with suspicious lesions who need to be seen by a specialist.
• Dermoscopy is already widely used by dermatologists to diagnose melanoma but its use in primary care has not been widely evaluated therefore more specific research is needed.
• Checklists to help interpret dermoscopy might improve the accuracy of diagnosis for practitioners with less expertise and training.
• Teledermatology - remote specialist assessment of skin lesions using dermoscopic images and photographs - is likely to be a good way of helping GPs to decide which skin lesions need to be seen by a skin specialist but future research needs to be better designed.
• Artificial intelligence techniques, such as computer-assisted diagnosis (CAD), can identify more melanomas than doctors using dermoscopy images. However, CAD systems also produce far more false positive diagnoses than dermoscopy and could lead to considerable increases in unnecessary surgery.
• Further research is needed on the use of specialist tests such as reflectance confocal microscopy (RCM) – a non-invasive imaging technique, which allows a clinician to do a ‘virtual biopsy’ of the skin and obtain diagnostic clues while minimising unnecessary skin biopsies. RCM is not currently widely used in the UK but the evidence suggests that RCM may be better than dermoscopy for the diagnosis of melanoma in lesions that are difficult to diagnose.
• Other tests such as using high frequency ultrasound have some promise, particularly for the diagnosis of BCCs, but the evidence base is small and more work is needed.

Cochrane Skin Group founder Professor Hywel Williams, of the Centre of Evidence-Based Dermatology at the University of Nottingham, said: “Completing this broad suite of detailed reviews was a real marathon.

“Apart from a few exceptions, I was surprised by how poor the overall study designs were, especially in terms of accurately documenting where on the clinical pathway patients were tested.

“Although some useful conclusions have emerged, for example, on the role of dermoscopy, the greatest value of the research is to serve as a yardstick for designing future studies evaluating skin cancer diagnosis techniques on patients who are typically seen in GP and specialist settings.”

The research team said that future studies evaluating diagnostic skin cancer tests should recruit patients with suspicious skin lesions at the point on the clinical pathway where the test under evaluation will be used in practice.

Further research is also needed to evaluate whether checklists to assist diagnosis by visual inspection alone can improve accuracy and to identify how much accuracy varies according to the level of expertise of the clinician carrying out the assessment.

Well-designed studies of dermoscopy in primary care are needed, and the best ways of delivering dermoscopy training need to be identified.

The reviews have been shared with The National Institute for Health and Care Excellence (NICE) to inform a potential update of the NICE Melanoma guideline, which was last updated in 2015.

For media enquiries contact Emma McKinney, Communications Manager (Health Sciences), University of Birmingham, tel: +44 (0) 121 414 6681, or contact the press office out of hours on +44 (0) 7789 921 165.

• The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 5,000 international students from over 150 countries.
• Cochrane is a global independent network of researchers, professionals, patients, carers and people interested in health. Cochrane produces reviews which study all of the best available evidence generated through research and make it easier to inform decisions about health. These are called systematic reviews. Cochrane is a not-for profit organization with collaborators from more than 130 countries working together to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest. Our work is recognised as representing an international gold standard for high quality, trusted information.
• The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:

1. Funds, supports and delivers high quality research that benefits the NHS, public health and social care
2. Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
3. Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
4. Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
5. Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

• The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR commissions applied health research to benefit the poorest people in low- and middle-income countries, using Official Development Assistance funding. This work uses data provided by patients and collected by the NHS as part of their care and support and would not have been possible without access to this data. The NIHR recognises and values the role of patient data, securely accessed and stored, both in underpinning and leading to improvements in research and care. 
• The Special Collection of Reviews published in the Cochrane Database of Systematic Reviews are:

1. Dinnes et al (2018). ‘Visual inspection for diagnosing cutaneous melanoma in adults.’ Cochrane Database of Systematic Reviews.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013194
2. Dinnes et al (2018). ‘Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD011902.pub2
3. Dinnes et al (2018). ‘Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013190
4. Chuchu et al (2018). ‘Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013192
5. Dinnes et al (2018). ‘Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD011901.pub2
6. Dinnes et al (2018). ‘Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013191
7. Chuchu et al (2018). ‘The use of Teledermatology for diagnosing skin cancer in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013193
8. Ferrante di Ruffano et al (2018). ‘Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013186 
9. Dinnes et al (2018). ‘High-frequency ultrasound for diagnosing skin cancer in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013188
10. Ferrante di Ruffano et al (2018). ‘Optical coherence tomography for diagnosing skin cancer in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013189
11. Ferrante di Ruffano et al (2018). ‘Exfoliative cytology for diagnosing Basal Cell Carcinoma and other skin cancers in adults.’ Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.CD013187

• This Special Collection was developed by the Cochrane Editorial & Methods Department, in collaboration with Dr Jac Dinnes (Institute of Applied Health Research, University of Birmingham) of the Cochrane Skin Group. It contains reviews by the Cochrane Skin Group. The project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Skin Group and Cochrane Programme Grant funding. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or Department of Health.